We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
ResMed Inc

ResMed Inc (RMD)

( -1.46% )
Updated: 12:17:38

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
208.32 Day's Range 213.53
132.24 52 Week Range 229.97
Market Cap
Previous Close
Last Trade
Last Trade Time
Financial Volume
$ 81,470,746
Average Volume (3m)
Shares Outstanding
Dividend Yield
PE Ratio
Earnings Per Share (EPS)
Net Profit

About ResMed Inc

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting ... ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting. Show more

Surgical,med Instr,apparatus
Surgical,med Instr,apparatus
Wilmington, Delaware, USA
ResMed Inc is listed in the Surgical,med Instr,apparatus sector of the New York Stock Exchange with ticker RMD. The last closing price for ResMed was $213.27. Over the last year, ResMed shares have traded in a share price range of $ 132.24 to $ 229.97.

ResMed currently has 146,907,207 shares outstanding. The market capitalization of ResMed is $30.79 billion. ResMed has a price to earnings ratio (PE ratio) of 34.31.

ResMed (RMD) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


RMD Latest News

PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia

SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP...

Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy

Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive...

ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When:          May 17–22, 2024Where:         San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101                       Marriott...

MatrixCare Joins Health Gorilla’s Qualified Health Information Network (QHIN) to Enhance Patient Data Access

BLOOMINGTON, Minn., May 16, 2024 (GLOBE NEWSWIRE) -- MatrixCare, a leading global technology provider in post-acute care, has partnered with Health Gorilla, the nation’s only dual-designated...

ResMed Announces Participation in the RBCCM Global Healthcare Conference

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Dr. Carlos Nunez, Chief Medical Officer, and Amy Wakeham, Chief Investor Relations Officer, will...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
AREBAmerican Rebel Holdings Inc
$ 0.7427
NXLNexalin Technologies Inc
$ 2.08
SHCRSharecare Inc
$ 1.365
SPECSpectaire Holdings Inc
$ 0.54
SRPTSarepta Therapeutics Inc New
$ 166.94
KAVLKaival Brands Innovations Group Inc
$ 1.525
PBMPsyence Biomedical Ltd
$ 0.4019
RELIReliance Global Group Inc
$ 0.4502
FBLGFibroBiologics Inc
$ 4.35
OLBOLB Group Inc
$ 2.58
NVDANVIDIA Corporation
$ 129.3719
AREBAmerican Rebel Holdings Inc
$ 0.7427
CRKNCrown Electrokinetics Corporation
$ 0.0418
ASTIAscent Solar Technologies Inc
$ 0.1131
NKLANikola Corporation
$ 0.3809

RMD Discussion

View Posts
whytestocks whytestocks 4 years ago
News; $RMD ResMed (RMD) Q1 2021 Earnings Call Transcript

Image source: The Motley Fool. ResMed (NYSE: RMD) Q1 2021 Earnings Call Oct 29, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: ResMed (RMD) Q1 2021 Earnings Call Transcript

Find out more RMD - ResMed (RMD) Q1 2021 Earnings Call Transcript
TheFinalCD TheFinalCD 4 years ago
RMD was just on Cramers MAd mONEy tonight

whytestocks whytestocks 5 years ago
News: $RMD Why ResMed Stock Is Shooting Higher Today

After management reported fiscal 2020 first-quarter results , shares of ResMed (NYSE: RMD) , a medical device maker focused on sleep-disorder breathing, rose 12% as of 12:00 p.m. EDT on Friday. The headline numbers from the period were great: Traders sent the share price to a new all-time ...

In case you are interested RMD - Why ResMed Stock Is Shooting Higher Today
whytestocks whytestocks 5 years ago
News: $RMD How ResMed Blew Past Expectations With Its Q1 Results

Despite a horrible start, 2019 has turned out to be a reasonably good year so far for ResMed (NYSE: RMD) . The healthcare company has consistently beaten Wall Street earnings estimates in recent quarters and delivered solid growth. ResMed announced its fiscal 2020 first-quarter results after...

Got this from RMD - How ResMed Blew Past Expectations With Its Q1 Results
ming1234 ming1234 5 years ago
100+ tomorrow.
crudeoil24 crudeoil24 6 years ago
ValueInvestor15 ValueInvestor15 7 years ago
ResMed $RMD has little Margin of Safety for value investors before earnings Monday:

Fair Value Analysis
phrantic phrantic 14 years ago
Medical Device Maker Delivers Wake-Up Call
MANUFACTURING: ResMed, Major Rival Team Up to Educate Clinicians About Sleep Disorders

In addition to announcing record revenues recently, ResMed is teaming up with a major competitor to educate the medical community in a $1 million campaign to help reach millions of undiagnosed Americans with sleeping disorders, especially sleep apnea.

Company officials said Sept. 30 that the campaign with Respironics, another device maker, and Cephalon, a drug company, is a wake-up call to action for a public health threat that the U.S. Department of Health & Human Services said results in an estimated $16 billion annually in medical costs, not including costs associated with lost work time.
Rckhnd Rckhnd 14 years ago
SYDNEY (Dow Jones)--Sleep disorder device company ResMed Inc. (RMD.AU) has agreed to revise its internal fair-trading checks following an investigation of price-fixing by Australia's competition regulator.

The Australian Competition and Consumer Commission said Tuesday it had investigated the company over whether it was telling accredited retailers that it would stop supplying its products if they sold them at less than a price specified by ResMed, a practice known as retail price maintenance.

"The ACCC is concerned that between March and June 2009 ResMed is likely to have engaged in retail price maintenance," the ACCC said in a statement.

ResMed has accepted a court-enforceable undertaking to write to its accredited retailers telling them they are free to set their own prices, and to amend its compliance program for Australian trade practices law, the ACCC said.

ResMed did not immediately respond to a call for comment.

-By David Fickling, Dow Jones Newswires; +61 2 8272 4689;

Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: You can use this link on the day this article is published and the following day.

(END) Dow Jones Newswires
Rckhnd Rckhnd 14 years ago
ResMed Inc. (NYSE: RMD) announced today that its two-for-one stock split of the company's outstanding shares of common stock, payable in the form of a 100% stock dividend was completed on August 30, 2010. The new total shares outstanding doubled to 151,388,240 shares, excluding shares held as treasury stock. The closing price of the company's common stock on the New York Stock Exchange on August 30, 2010 was $60.38. On a split-adjusted basis, the company's closing stock price on August 30, 2010 would have been $30.19. The company's total market capitalization as of August 30, 2010 was approximately $4.6 billion on that date.
Rckhnd Rckhnd 14 years ago
Yes! 2:1 split has happened!
Now just waiting for those free shares to show up!
Rckhnd Rckhnd 14 years ago
Steady climb pre-split. Financials decent. Should resume upward trend after split.
Rckhnd Rckhnd 14 years ago
SYDNEY, Aug 12, 2010 /PRNewswire via COMTEX/ -- ResMed, Inc. (NYSE: RMD), (ASX:
RMD) announced today that the company has been granted a waiver of rules 13.9.4
and 13.9.9 of the Australian Stock Exchange Settlement Operating Rules, in
connection with the stock split announced to the Market on 6 August 2010.



As advised in the Company's 6 August announcement:

Stockholders of record on the New York Stock Exchange at the close of trading on
August 17, 2010 will receive one additional share of common stock for each share
held on that date. The common stock will be distributed to shareholders on or
about August 30, 2010, by ResMed's NYSE transfer agent, American Stock Transfer
and Trust Company, LLC. The common stock is expected to begin trading on a
post-split basis on the NYSE beginning on August 31, 2010, or one day following
the distribution date.

Holders of CHESS Depositary Interests (CDIs) on the Australian Stock Exchange
will also receive a bonus issue of one additional CDI for every CDI held on the
ASX record date of August 18, 2010. Unlike the shares on the NYSE, the existing
CDIs will be quoted on an "ex-bonus" basis on August 12, 2010 on the ASX (ASX:
RMD), and bonus CDI's will be quoted on a deferred settlement basis (ASX:
RMDBN). The bonus CDIs will be distributed by ResMed's ASX share registry,
Computershare Limited, on or about August 31, 2010, and normal trading will
begin on the following day.

Due to the difference in market practice between the NYSE and ASX, ResMed
applied for and has been granted a waiver of rules 13.9.4 and 13.9.9 of the ASX
Settlement Operating Rules, allowing it to defer the processing of conversions
(transmutations) between its Common Stock and CDI registers that are lodged in
the period from and including 12 August 2010 up to and including 31 August 2010.
Therefore, no conversions (transmutations) will be processed during this time.
Processing of conversions will re-commence on 1 September 2010.

About ResMed

ResMed is a leading developer, manufacturer and distributor of medical equipment
for the treatment and management of sleep-disordered breathing and other
respiratory disorders. The company is dedicated to developing innovative
products to improve the lives of those who suffer from these conditions and to
increasing awareness among patients and healthcare professionals of the
potentially serious health consequences of untreated sleep-disordered breathing.

Further information can be obtained by contacting Constance Bienfait at ResMed,
Inc., San Diego, on (+ 1 858-836-5971), or Brett Sandercock at ResMed Limited,
Sydney, on (+61 2) 8884-2090; or by visiting the Company's multilingual Web site

SOURCE ResMed, Inc.
Rckhnd Rckhnd 14 years ago

Looking forward to the split!!

Rckhnd Rckhnd 14 years ago
2:1 stock split

Australian sleep management company RESMED INC (ASX:RMD) on Friday booked record revenue and income for the 2010 full financial year and announced a two-for-one stock split. ResMed said that for the year ended June 30, 2010, income from operations was US$240.4 million, and net income was US$190.1 million, an increase of 26 per cent and 30 per cent respectively, compared to the 2009 full financial year.

* Annual revenue in 2010 was US$1.1 billion, up 19 per cent (or 17 per cent on a constant currency basis) over 2009.

* ResMed also announced on Friday that its board of directors had approved a two-for-one stock split of the company's outstanding shares of common stock, payable in the form of a 100 per cent stock dividend.

Your Recent History

Delayed Upgrade Clock